help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quaedackers, M. E.
Right arrow Articles by Van Der Burg, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quaedackers, M. E.
Right arrow Articles by Van Der Burg, B.
Endocrinology Vol. 142, No. 3 1156-1166
Copyright © 2001 by The Endocrine Society

ARTICLES

4-Hydroxytamoxifen Trans-Represses Nuclear Factor-{kappa}B Activity in Human Osteoblastic U2-OS Cells through Estrogen Receptor (ER){alpha}, and Not through ER{beta}1

Monique E. Quaedackers, Christina E. Van Den Brink, Sacha Wissink, Richard H. M. M. Schreurs, Jan-Åke Gustafsson, Paul T. Van Der Saag and Bart Van Der Burg

Hubrecht Laboratory (M.E.Q., C.E.V.D.B., S.W., R.H.M.M.S., P.T.V.D.S., B.V.D.B.), Netherlands Institute for Developmental Biology, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands; and Department of Medical Nutrition (J.-Å.G.), Karolinska Institute, Novum, S-14186 Huddinge, Sweden

Address all correspondence and requests for reprints to: Dr. Bart van der Burg, Hubrecht Laboratory, Netherlands Institute for Developmental Biology, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands. E-mail: bvdb{at}niob.knaw.nl

Estrogens are important mediators of bone homeostasis, and postmenopausal estrogen replacement therapy is extensively used to prevent osteoporosis. The biological effects of estrogen are mediated by receptors belonging to the superfamily of steroid/thyroid nuclear receptors, estrogen receptor (ER){alpha} and ER{beta}. ER{alpha}, not only trans-activates target genes in a hormone-specific fashion, but it can also neutralize other transcriptional activators, such as nuclear factor (NF)-{kappa}B, causing repression of their target genes. A major mechanism by which estrogens prevent osteoporosis seems to be repression of transcription of NF-{kappa}B target genes, such as the osteoclast-activating cytokines interleukin-6 and interleukin-1. To study the capacity of both ERs in repression of NF-{kappa}B signaling in bone cells, we first carried out transient transfections with ER{alpha} or ER{beta} of the human osteoblastic U2-OS cell line, in which endogenous NF-{kappa}B was stimulated by tumor necrosis factor {alpha}. Repression by ER{alpha} was already observed without 17{beta}-estradiol, whereas addition of the ligand increased repression to 90%. ER{beta}, however, was able to repress NF-{kappa}B activity only in the presence of ligand. Because it is known that some antiestrogens can also display tissue-specific agonistic properties, 4-hydroxytamoxifen was tested for its capacity in repressing NF-{kappa}B activity and was found to be active (albeit less efficient than 17{beta}-estradiol) and, interestingly, only with ER{alpha}. The pure antagonist ICI 164,384 was incapable of repressing through any ER subtypes. Deletion analysis and the use of receptor ER{alpha}/ER{beta}-chimeras showed that the A/B domain, containing activation function-1, is essential for this suppressive action. Next, we developed stable transfectants of the human osteoblastic U2-OS cell line containing ER{alpha} or ER{beta} in combination with an NF-{kappa}B luciferase reporter construct. In these cell lines, repression of NF-{kappa}B activity was only mediated through ER{alpha} and not through ER{beta}. These findings offer new insights into the specific role of both ER subtypes in bone homeostasis and could eventually help in developing more specific medical intervention strategies for osteoporosis.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
J. Frasor, E. C. Chang, B. Komm, C.-Y. Lin, V. B. Vega, E. T. Liu, L. D. Miller, J. Smeds, J. Bergh, and B. S. Katzenellenbogen
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
Cancer Res., July 15, 2006; 66(14): 7334 - 7340.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. C. Lambert, E. M. Curran, B. M. Judy, G. N. Milligan, D. B. Lubahn, and D. M. Estes
Estrogen Receptor {alpha} (ER{alpha}) Deficiency in Macrophages Results in Increased Stimulation of CD4+ T Cells while 17{beta}-Estradiol Acts through ER{alpha} to Increase IL-4 and GATA-3 Expression in CD4+ T Cells Independent of Antigen Presentation
J. Immunol., November 1, 2005; 175(9): 5716 - 5723.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. J. Perry, S. Gujra, T. Whitworth, and J. H. Tobias
Tamoxifen Stimulates Cancellous Bone Formation in Long Bones of Female Mice
Endocrinology, March 1, 2005; 146(3): 1060 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
E. Sonneveld, H. J. Jansen, J. A. C. Riteco, A. Brouwer, and B. van der Burg
Development of Androgen- and Estrogen-Responsive Bioassays, Members of a Panel of Human Cell Line-Based Highly Selective Steroid-Responsive Bioassays
Toxicol. Sci., January 1, 2005; 83(1): 136 - 148.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Chu, Y. Nishi, T. Yanase, H. Nawata, and P. J. Fuller
Transrepression of Estrogen Receptor {beta} Signaling by Nuclear Factor-{kappa}B in Ovarian Granulosa Cells
Mol. Endocrinol., August 1, 2004; 18(8): 1919 - 1928.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
K. C. Lambert, E. M. Curran, B. M. Judy, D. B. Lubahn, and D. M. Estes
Estrogen receptor-{alpha} deficiency promotes increased TNF-{alpha} secretion and bacterial killing by murine macrophages in response to microbial stimuli in vitro
J. Leukoc. Biol., June 1, 2004; 75(6): 1166 - 1172.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. Rogatsky, J.-C. Wang, M. K. Derynck, D. F. Nonaka, D. B. Khodabakhsh, C. M. Haqq, B. D. Darimont, M. J. Garabedian, and K. R. Yamamoto
Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor
PNAS, November 25, 2003; 100(24): 13845 - 13850.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. A. Harris, L. M. Albert, Y. Leathurby, M. S. Malamas, R. E. Mewshaw, C. P. Miller, Y. P. Kharode, J. Marzolf, B. S. Komm, R. C. Winneker, et al.
Evaluation of an Estrogen Receptor-{beta} Agonist in Animal Models of Human Disease
Endocrinology, October 1, 2003; 144(10): 4241 - 4249.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. A. Loven, N. Muster, J. R. Yates, and A. M. Nardulli
A Novel Estrogen Receptor {alpha}-Associated Protein, Template-Activating Factor I{beta}, Inhibits Acetylation and Transactivation
Mol. Endocrinol., January 1, 2003; 17(1): 67 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
N. Vasudevan, S. Ogawa, and D. Pfaff
Estrogen and Thyroid Hormone Receptor Interactions: Physiological Flexibility by Molecular Specificity
Physiol Rev, October 1, 2002; 82(4): 923 - 944.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Pfeilschifter, R. Koditz, M. Pfohl, and H. Schatz
Changes in Proinflammatory Cytokine Activity after Menopause
Endocr. Rev., February 1, 2002; 23(1): 90 - 119.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society